ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.37
1.00%
US Tech 100
20,113.20
-0.07%
S&P 500
5,928.71
0.20%
US Dollar vs CAD
1.39519
-0.13%
Bitcoin
97,062.00
2.88%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. AtriCure Inc (ATRC) Share Price

AtriCure Inc

AtriCure Inc (ATRC)

NASDAQ
36.15
0.12
( 0.33% )
Updated: 10:06:40
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
36.15
Bid
36.11
Ask
36.17
Volume
32,781
35.765 Day's Range 36.34
18.94 52 Week Range 42.9999
Market Cap
1.762B
Previous Close
36.03
Open
36.075
Last Trade
100
@
36.15
Last Trade Time
10:06:40
Financial Volume
US$ 1,182,166
VWAP
36.0625
Average Volume (3m)
575,770
Shares Outstanding
48,753,251
Dividend Yield
-
PE Ratio
-57.71
Earnings Per Share (EPS)
-0.62
Revenue
399.25M
Net Profit
-30.44M

About AtriCure Inc

AtriCure Inc is a innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft T... AtriCure Inc is a innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
www.atricure.com
Headquarters
Wilmington, Delaware, USA
Founded
-
AtriCure Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker ATRC. The last closing price for AtriCure was US$36.03. Over the last year, AtriCure shares have traded in a share price range of US$ 18.94 to US$ 42.9999.

AtriCure currently has 48,753,251 shares outstanding. The market capitalization of AtriCure is US$1.76 billion. AtriCure has a price to earnings ratio (PE ratio) of -57.71.

Ask ADVFN Intelligence (AI)

ATRC Latest News

More News

AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

November 20 2024
Business Wire

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

November 14 2024
Edgar (US Regulatory)

AtriCure to Participate in the Stifel 2024 Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

November 07 2024
Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

October 30 2024
Edgar (US Regulatory)

Form 8-K - Current report

October 29 2024
Edgar (US Regulatory)

AtriCure Reports Third Quarter 2024 Financial Results

Worldwide revenue of $115.9 million – an increase of 17.9% year over year U.S. revenue of $95.5 million – an increase of 16.8% year over year Achieved 20% growth on revenues from open appendage...

October 29 2024
Business Wire

AtriCure to Participate in the UBS Global Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

October 28 2024
Business Wire

AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

October 15 2024
Business Wire

AtriCure to Announce Third Quarter 2024 Financial Results

  AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain...

October 08 2024
Business Wire

AtriCure a obtenu la certification de marquage CE pour la pince EnCompass®

Une approbation qui sert de nouveau vecteur de croissance à l'international pour AtriCure AtriCure, Inc. ( Nasdaq: ATRC ), leader en matière d'innovation pour les interventions chirurgicales et...

October 01 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.23-0.63221550302436.3836.44534.2547005335.40019806CS
47.232528.9238.3427.6473331833.86286404CS
1210.3640.170608763125.7938.3425.2657577030.37343606CS
2613.8962.398921832922.2638.3418.9472620625.50280351CS
52-5.51-13.226116178641.6642.999918.9471091727.9941842CS
156-41.52-53.456933178877.6779.62518.9443461736.87571618CS
2607.1124.483471074429.0489.1818.9439976542.29509748CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WORXSCWorx Corporation
US$ 1.93
(96.94%)
103.79M
CRNCCerence Inc
US$ 5.0099
(77.66%)
31.16M
BDRXBiodexa Pharmaceuticals PLC
US$ 6.8101
(76.89%)
1.49M
IBGInnovation Beverage Group Limited
US$ 1.10
(39.03%)
6.22M
SPAISafe Pro Group Inc
US$ 4.37
(36.56%)
38.23M
PYXSPyxis Oncology Inc
US$ 2.06
(-46.07%)
9.15M
KURAKura Oncology Inc
US$ 9.865
(-37.99%)
7.4M
BLRXBioLineRx Ltd
US$ 0.3585
(-34.24%)
5.6M
GLXGGalaxy Payroll Group Ltd
US$ 2.60
(-33.50%)
387.24k
SHOTWSafety Shot Inc
US$ 0.1001
(-33.27%)
2.5k
CDTConduit Pharmaceuticals Inc
US$ 0.111999
(21.34%)
486.12M
NVDANVIDIA Corporation
US$ 143.9509
(-1.33%)
198.63M
AKTSAkoustis Technologies Inc
US$ 0.0999
(14.70%)
181.9M
ELABElevai Labs Inc
US$ 0.0202
(-5.61%)
135.79M
WORXSCWorx Corporation
US$ 1.93
(96.94%)
103.79M

ATRC Discussion

View Posts
mlkrborn mlkrborn 11 years ago
HISTORY
Initial Public Offering



On August 10, 2005, we consummated an initial public offering of 4.6 million shares of our common stock at $12.00 per share, which includes the underwriters exercise of their over-allotment option, on August 9, 2005, to purchase 600,000 shares of our common stock of which 450,000 shares were sold by selling shareholders and 150,000 shares were sold by us. We did not receive any proceeds from the sale of the 450,000 shares of common stock that were sold by selling shareholders. These share amounts reflect a 1-for-3.8 reverse split of our capital stock that was effected on July 27, 2005. Proceeds to us from the offering, after deducting underwriting discounts and commissions but before expenses, were $46.3 million. Expenses are estimated to be approximately $3.25 million.



15
👍️0
mlkrborn mlkrborn 11 years ago
AtriCure receives FDA approval for investigational study to evaluate stroke prevention in atrial fibrillation (ATRC) 14.35 : Co announces the FDA approval to begin enrollment in a clinical study of AtriCure's AtriClip Left Atrial Appendage Exclusion System. The study will evaluate the use of the AtriClip device to prevent stroke in patients with Afib. The feasibility study will enroll Afib patients at seven medical centers across the country. The study will focus on patients with risk factors that place them at significant risk of stroke as well as substantial bleeding risks that contraindicate them for anticoagulation therapy. Research suggests that up to 40% of patients are unable to take oral anticoagulants due to excessive risk of bleeding.
👍️0
dmarkg dmarkg 12 years ago
Hey Wobblenuts and Jackie Scan I want to show you something....

Medical Breakthrough Wound Stasis Technology

ATRC and EPGL could possibly go hand in hand here...
Merry Christmas 2012

Merry Chirstmas 2012, friends.
👍️0
wobblenuts wobblenuts 12 years ago
Any talks involving ATRC and soon to be sub penny wonder EPGL?



Are they hinting at something here?


1)"ATRC fully SEC reporting financials are available at OTCMARKETS for EPGL investors to see as an example of where EPGL management is headed."

2)"EPGL initiating R&D on 4 new medical devices before end of 2012."

3)"Property and equipment, net 0"
👍️0
Penny Roger$ Penny Roger$ 13 years ago
~ Monday! $ATRC ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $ATRC ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=ATRC&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=ATRC&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=ATRC
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=ATRC#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=ATRC+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=ATRC
Finviz: http://finviz.com/quote.ashx?t=ATRC
~ BusyStock: http://busystock.com/i.php?s=ATRC&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=ATRC >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.
👍️0
Penny Roger$ Penny Roger$ 13 years ago
AtriCure, Inc., is a medical device company. The Company develops, manufactures and sells cardiac surgical ablation systems designed to create lesions, or scars, in cardiac, or heart, tissue and devices for the exclusion of the left atrial appendage. The Company has two primary product lines for the ablation of cardiac tissue. Its primary product line, which accounts for a majority of its revenues, is Isolator Synergy bipolar ablation clamp system (Isolator system) and related radiofrequency ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. In addition, it offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System, or AtriClip system, which is designed to exclude the left atrial appendage.

http://www.google.com/finance?q=ATRC
👍️0

Your Recent History

NASDAQ
ATRC
AtriCure
DOWI
DJUSDN
DJ US Defense
LSE
0KO0
Elon Ab
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved